According to the WHO, obesity has reached epidemic proportions globally, with at least 2.8 million people dying each year as a result of being overweight or obese. The number of obese children and adolescents (aged five to 19 years) worldwide has risen tenfold in the past four decades. Obesity is a major risk factor for heart disease, stroke, osteoarthritis, diabetes, liver disease such as non-alcoholic steatohepatitis (NASH), and certain cancers. Muscular dystrophies, such as Duchenne, myotonic, facioscapulohumeral, etc., currently have no cure. Staging and progression of these conditions can be measured by the amount of muscle tissue that has been replaced by fat. As pharmaceutical companies attempt to develop treatments for these noncommunicable, obesity-related diseases and for the different muscular dystrophies, it is important to monitor body composition as both an efficacy and safety endpoint. The traditional body composition measurement has been BMI. Although BMI is a rough estimate of how over- or underweight a person is, it does not provide information about how much of the weight comes from muscle, how much comes from fat and how these tissues are affected by the treatment.
Join BioTelemetry Research’s Vice President of Musculoskeletal and Metabolic Imaging, Jonathan Riek, PhD, and AMRA’s Chief Scientific Officer & Co-Founder, Olof Dahlqvist Leinhard, PhD, as they present alternative, noninvasive imaging methods to determine body composition. These imaging methods range from the most simplistic thickness measurements from ultrasound, to the more advanced measurements of fat distribution, muscle tissue, and diffuse infiltration of fat in muscle and liver tissue from DXA, CT and MRI.
The speakers will discuss:
- Advantages of noninvasive imaging methods
- When to use ultrasound, DXA, CT and MRI to measure body composition and how to successfully implement these modalities in clinical trials
- Body composition measurements from rapid, highly standardized, whole-body MRI
Register today to learn about the alternative, noninvasive imaging methods available to determine body composition in your clinical trial.
Jonathan Riek, PhD, Vice President, Musculoskeletal and Metabolic Imaging, BioTelemetry Research (Cardiocore & VirtualScopics)
Jonathan Riek, PhD, serves as the Vice President of Musculoskeletal & Metabolic Imaging for BioTelemetry Research. He has a PhD in Electrical Engineering from the University of Rochester, and his doctoral thesis was on motion and artifact reduction in MRI. He worked on the development of a 3D CT scanner as a postdoctoral researcher and then spent 7 years in the research labs at the Eastman Kodak Company. While at Kodak, Jonathan worked in the areas of motion estimation, frame rate conversion and video compression. He also served as the liaison between the image science division and the corporate software group. He joined VirtualScopics in 2000 to return to medical imaging and apply his skills interfacing between image science and software. In 2004, he led the development of the system that VirtualScopics still uses to run clinical trials and analyze medical images. In his current role, Jonathan has scientific responsibility for all of Biotelemetry Research’s musculoskeletal and metabolic imaging studies, including arthritis, muscle diseases, diabetes and liver diseases such as NASH and NAFLD. He holds four patents and has published many articles on various topics in MRI.
Olof Dahlqvist Leinhard, PhD, Chief Scientific Officer & Co-Founder, AMRA
Olof Dahlqvist Leinhard, PhD is the Chief Scientific Officer & Co-Founder at AMRA. He is also a Senior University Lecturer in Magnetic Resonance (MR) Physics at Linköping University (LiU), within the Department of Medicine and Health (IMH) / Division of Radiological Sciences (RAD). Renowned within the field of MR Physics, Olof has over 45 peer-reviewed journal and conference articles, as well as over 90 peer-reviewed conference abstracts to his name.
Who Should Attend?
This webinar will benefit medical and non-medical professionals in the biopharmaceutical industry, especially those supporting imaging drug development with roles in:
- Clinical Research
- Clinical Development
- Medical Affairs
- Clinical Operations
- Project Management
- Regulatory Affairs
As a division of BioTelemetry, Inc. (NASDAQ: BEAT), BioTelemetry Research provides expert Cardiac and Imaging core lab solutions for the advancement of clinical drug development. Our cardiac network processes over 2 billion heartbeats a day, while supporting over 20,000 sites and 30,000 devices monthly, and monitoring nearly 600,000 patients and research subjects a year. We offer global operational support for cardiovascular monitoring in all therapeutic areas, and advanced imaging analyses in cardiovascular, oncology, neurology, metabolic, musculoskeletal and medical device studies. Our research team is comprised of key opinion leaders, board certified radiologists and cardiologists, sub-specialty scientists, and highly trained technicians. These experts acquire, evaluate, and report high-quality data through an efficient, cloud-based infrastructure. For more information please visit www.gobio.com/research.
AMRA is the first in the world to transform images from a rapid, 6-minute whole body MRI scan into precise, 3D-volumetric fat and muscle measurements. AMRA’s cloud-based analysis service offers precise, automated insights that have far-reaching implications for the pharmaceutical industry, academic R&D and, soon, clinical practice. AMRA was founded in 2010 as a spin-off of the Center for Medical Image Science and Visualization (CMIV), the Department of Biomedical Engineering (IMT) and the Department of Medicine and Health (IMH) at Linköping University, Sweden. For more information, visit www.amra.se.